San Carlos, CA-based BioCardia has filed an IPO designed to raise $57.5 million. The regenerative medicine biotech expects to start enrolling patients into a pivotal Phase III study for a new cell therapy for ischemic systemic heart failure later this year, with data due in 2017. Stanford Professor Simon Sterzer controls 18.5% of the stock through a family trust, the largest block of shares. CEO Peter Altman, meanwhile, controls 7.8% of the stock. S-1